Aurobindo gets FDA approval for Bromfenac Ophthalmic Solution

Print Friendly, PDF & Email

EAST WINDSOR, N.J. – Aurobindo Pharma has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Bromfenac Ophthalmic Solution 0.09%. Aurobindo Pharma’s Bromfenac Ophthalmic Solution, are an AT-rated generic equivalent to the reference listed drug (RLD), Bromday Ophthalmic Solution, of Bausch & Lomb.

Bromfenac Ophthalmic Solution are indicated for postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.
Bromfenac Ophthalmic Solution has an estimated market size of US $1.6 Million for the twelve months ending February 2022, as per IQVIA.


Comments are closed.

Adheris Health